COMIRNATY

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0191/G	This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	05/12/2023		SmPC, Labelling and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IB/0196/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.z - Quality change - Active substance - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	22/11/2023	n/a		
IB/0198	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	17/11/2023	29/11/2023	SmPC	

IB/0195/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	26/10/2023	n/a		
II/0188/G	This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	26/10/2023	29/11/2023	SmPC	Please refer to Scientific Discussion 'Comirnaty-H-C-005735-II-188-G'
II/0187	C.I.13 - Other variations not specifically covered	26/10/2023	n/a		

	elsewhere in this Annex which involve the submission of studies to the competent authority				
IB/0190/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	04/10/2023	19/10/2023	SmPC, Annex II and PL	To extend the shelf life of COMIRNATY Original/Omicron BA.4-5 (1.5/1.5 µg)/dose concentrate for dispersion for injection (EU/1/20/1528/017) from 18 months to 2 years.

	B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation B.II.f.z - Stability of FP - Other variation				
II/0186/G	This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	14/09/2023	n/a		Studies WI235284 (Emory) and WI255886 (Bristol) were conducted in hospital settings in the United States (May 2021 – August 2022) and The United Kingdom (January 2021 – August 2022), respectively. The overall vaccine effectiveness in the Bristol and Emory studies were 81.7% (95% CI: 77.1%, 85.4%) and 64.1% (95% CI: 51.3%, 73.5%), respectively. The studies found that two doses of Comirnaty provided a robust protection against COVID19-mediated acute respiratory infection during the Alpha- and Delta-waves but the vaccine effectiveness decreased during the Omicron-wave.
II/0183	B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine	30/08/2023	31/08/2023	SmPC, Labelling and PL	Please refer to Scientific Discussion 'Comirnaty-H-C-005735-II-0183'

PSUSA/10898 /202212	Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5)	20/07/2023	29/08/2023	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10898/202212.
X/0180	Annex I_2.(d) Change or addition of a new pharmaceutical form	22/06/2023	08/08/2023	SmPC, Labelling and PL	Please refer to Scientific Discussion 'Comirnaty-H-C-005735-X-0180'
II/0177/G	This was an application for a group of variations. C.I.6.a: Extension of indication to include Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection and Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection for use as primary vaccination course against COVID-19 in children aged 5 to 11 years and in individuals 12 years of age and older, respectively, based on interim results from studies C4591044 and C4591048. Study C4591044 is an interventional, randomized, active-controlled, phase 2/3 study to investigate the safety, tolerability, and immunogenicity of bivalent BNT162b RNA-based vaccine candidates as a booster dose in COVID-19 vaccine–experienced healthy individuals, while study C4591048 is a phase 1/2/3 master study to investigate the safety, tolerability, and immunogenicity of bivalent BNT162b2 RNA-based	22/06/2023	08/08/2023	SmPC, Labelling and PL	Please refer to Scientific Discussion 'Comirnaty-H-C-005735-II-0177/G' For more information, please refer to the Summary of Product Characteristics.

	vaccine candidates in healthy children. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information. A.6: Change of the ATC Code of tozinameran, riltozinameran and famtozinameran from J07BX03 to J07BN01. In addition, the vaccine posology has been simplified for all approved formulations. As a consequence, sections 4.2, 4.4, 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one A.6 - Administrative change - Change in ATC Code/ATC Vet Code				
X/0176	Annex I_2.(c) Change or addition of a new strength/potency	22/06/2023	08/08/2023	SmPC, Labelling and PL	Please refer to Scientific Discussion 'Comirnaty-H-C-005735-X-0176'
IB/0185	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	05/07/2023	17/07/2023	SmPC	To extend the shelf-life of the biological finished product COMIRNATY 30 µg Concentrate for dispersion for injection (EU/1/20/1528/001) from 18 months to 24 months when stored at the storage condition of -90 to -60 °C.

IB/0184	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	05/07/2023	17/07/2023	SmPC	To extend the shelf-life from 18 to 24 months when stored at the storage condition of -90 to -60 °C of the following biological finished product: COMIRNATY 30 µg dispersion for injection (EU/1/20/1528/002-003) COMIRNATY 10 µg concentrate for dispersion for injection (EU/1/20/1528/004-005) COMIRNATY Original/Omicron BA.1, 15/15 µg dispersion for injection (EU/1/20/1528/006-007) COMIRNATY Original/Omicron BA.4-5, 15/15 µg dispersion for injection (EU/1/20/1528/008-009) COMIRNATY 3 µg concentrate for dispersion for injection (EU/1/20/1528/010) COMIRNATYOriginal/Omicron BA.4-5, 5/5 µg concentrate for dispersion for injection (EU/1/20/1528/011-012) COMIRNATY 30 µg dispersion for injection (EU/1/20/1528/013)- single dose vials COMIRNATY Original/Omicron BA.4-5 15/15 µg dispersion for injection (EU/1/20/1528/014)- single dose vials
II/0182/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.3.c - Change in the manufacturing process of	22/06/2023	n/a		

	the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process				
II/0181	B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	22/06/2023	n/a		
II/0178	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	01/06/2023	n/a		
II/0174/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.4.a - Change in synthesis or recovery of a non-	04/05/2023	n/a		

	pharmacopoeial or novel excipient - Minor change A.7 - Administrative change - Deletion of manufacturing sites				
IB/0179/G	This was an application for a group of variations. B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product B.I.z - Quality change - Active substance - Other variation	13/04/2023	n/a		
IB/0172/G	This was an application for a group of variations. B.I.d.z - Stability of AS - Other variation B.I.d.z - Stability of AS - Other variation	04/04/2023	n/a		
II/0167	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	16/03/2023	n/a		
IB/0173/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change	13/03/2023	n/a		

	in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process				
IB/0171/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation	13/03/2023	n/a		
II/0139	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	23/02/2023	09/03/2023	SmPC	No new safety concerns have been identified; the overall safety results are in line with data previously presented. Immunogenicity data 1 month after booster dose are updated due to neutralization assay validation. For more information, please refer to the Summary of Product Characteristics.

II/0160	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	09/02/2023	06/03/2023	SmPC, Labelling and PL	Pre-specified hypothesis-driven efficacy analysis was performed with additional confirmed COVID 19 cases accrued during blinded placebo-controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population. In the efficacy analysis of Study 3 in children 5 to 11 years of age without evidence of prior infection, there were 10 cases in 2,703 participants who received the vaccine and 42 cases out of 1,348 who received placebo. The point estimate for efficacy is 88.2% (95% confidence interval 76.2, 94.7) during the period when Delta variant was the predominant circulating strain. In participants with or without evidence of prior infection there were 12 cases in the 3,018 who received vaccine and 42 cases in 1,511 participants who received placebo. The point estimate for efficacy is 85.7% (95% confidence interval 72.4, 93.2). No new safety concerns have been identified; the overall safety results are in line with data previously presented. For more information, please refer to the Summary of Product Characteristics.
II/0165/G	This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a	16/02/2023	n/a		

	manufacturing site for the FP - Secondary packaging site B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process				
IB/0170/G	This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.b - Change in test procedure for an excipient - Deletion of a test procedure if an alternative test procedure is already authorised B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	07/02/2023	n/a		

IB/0169	B.I.z - Quality change - Active substance - Other variation	30/01/2023	n/a		
II/0152	C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	12/01/2023	30/01/2023	SmPC and PL	Update of section 4.8 of the SmPC in order to add "Dizziness" to the list of adverse drug reactions (ADRs) with frequency 'Uncommon', based on a cumulative review. The Package Leaflet is updated accordingly.
IB/0164/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.d.z - Stability of AS - Other variation	16/01/2023	n/a		
II/0159/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	12/01/2023	n/a		

	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products				
PSUSA/10898 /202206	Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5)	12/01/2023	n/a		PRAC Recommendation - maintenance
IB/0166	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	04/01/2023	n/a		
IB/0168	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	21/12/2022	22/12/2022	SmPC	Shelf life extension of the finished product (Comirnaty 30 µg Concentrate for dispersion for injection, EU/1/20/1528/001) from 15 months to 18 months when stored at -90 to -60°C
IB/0161	B.II.z - Quality change - Finished product - Other variation	13/12/2022	n/a		
N/0158	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/12/2022	n/a		

II/0156/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products	08/12/2022	22/12/2022	SmPC, Labelling and PL	The scope of this variation is to introduce a single dose vial (SDV) presentation. Sufficient data are provided to demonstrate that the single dose vial presentation is comparable to the currently approved multi dose presentations. The Product Information is updated as follows; Comirnaty, 30 micrograms/dose, dispersion for injection: The SmPC sections 2, 4.2, 6.3, 6.5 and 6.6 are updated to include information on single dose vials. Comirnaty Original/Omicron BA.4-5, (15/15 micrograms)/dose, dispersion for injection: The SmPC sections 2, 4.2, 6.3, 6.5 and 6.6 are updated to include information on single dose vials. The Labelling and PL have been updated accordingly.
II/0149/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is	08/12/2022	n/a		

	a biological/immunological medicinal product and the change requires an assessment of comparability				
II/0148/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.z - Quality change - Active substance - Other variation B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	08/12/2022	n/a		
IAIN/0163	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	02/12/2022	02/12/2022	SmPC and PL	To update section 4.8 of the SmPC and section 4 of the PL to implement the signal recommendation on heavy menstrual bleeding.
IB/0162/G	This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf	02/12/2022	02/12/2022	SmPC	To update the product information to extend the shelf life of the finished product from 12 months to 18 months when stored at the storage condition of -90 to -60 °C, for

	life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol				presentations EU/1/20/1528/002-012.
IB/0157/G	This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	28/11/2022	n/a		
IB/0154	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	16/11/2022	n/a		
IB/0155/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process	15/11/2022	n/a		

	of the AS B.I.z - Quality change - Active substance - Other variation				
IB/0153/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation	14/11/2022	n/a		
X/0147	Annex I_2.(c) Change or addition of a new strength/potency	10/11/2022	10/11/2022	SmPC, Labelling and PL	Please refer to Scientific Discussion 'Comirnaty/H/C/005735/X/0147'
II/0145	To update sections 4.2, 4.8 and 5.1 of the SmPC in order to add recommendations and data for subsequent and booster doses based on real world evidence (RWE) data as well as interim study results from both sub-study E (SSE) and sub-study D (SSD) C4591031 following procedure II/0140 assessment. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	27/10/2022	28/10/2022	SmPC and PL	SmPC new text This variation concerns the update of the SmPC to include additional booster doses of Comirnaty in individuals 12 years of age and older at least 3 months between the administration of Comirnaty and the last prior dose of a COVID-19 vaccine. This application is supported with safety and immunogenicity interim results following a fourth booster dose in two subsets from the phase III study C4591031 (substudy D and E). The immune responses after a fourth dose show an increase of the neutralising antibody titres against Wuhan and Omicron BA.1 compared to pre-boost levels. In adults

					55 years of age and older, the antibody titre increased 5.8-fold (95% CI: 4.6, 7.2) against Omicron BA.1 strain and 4.3-fold (95% CI: 3.7, 5.0) against Wuhan strain after Comirnaty Original 30µg vaccine one month after booster dose. In adults between 18- and 55-years of age, the antibody titres increased 3.4-fold (95% CI: 3.0, 3.8) for Omicron BA.1 and 3.0 (95% CI: 2.7, 3.3) for Wuhan strain. The overall safety profile for the fourth dose was similar to that observed after the Comirnaty booster (third dose). No new safety concerns have been identified. In addition, the MAH presented supportive evidence from observational studies that support an additional booster dose (fourth dose) of Comirnaty to improve protection against COVID-19. Relative vaccine effectiveness (VE) of 34-65% against symptomatic COVID-19 were observed in various studies compared to three doses of the same vaccine. Relative VE against severe infections and hospitalization (64-71%) and death (72-78%) were higher. For more information, please refer to the Summary of Product Characteristics.
IB/0151	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	27/10/2022	n/a		
N/0150	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	27/10/2022	n/a		
X/0138	Annex I_2.(c) Change or addition of a new strength/potency	19/10/2022	20/10/2022	SmPC, Labelling and PL	Please refer to Scientific Discussion 'Comirnaty/H/C/005735/X/0138'

R/0137	Renewal of the marketing authorisation.	15/09/2022	10/10/2022		The CHMP, having reviewed the available information on the status of the fulfilment of the Specific Obligations and having confirmed the positive benefit risk balance of Comirnaty, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, the CHMP considered that, as all Specific Obligations have been either fulfilled or reclassified as category 3 studies in the RMP, there are no remaining grounds for the marketing authorisation to remain conditional and therefore recommends the granting of a standard marketing authorisation not subject to Specific Obligations for Comirnaty. Please refer to Scientific Discussion 'Comirnaty/H/C/005735/R/0137'
II/0146/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch	29/09/2022	n/a		

	release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes				
II/0141	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	15/09/2022	16/09/2022	SmPC and PL	Update of sections 4.4 and 4.8 of the SmPC in order to update the existing information on myocarditis and pericarditis after a third dose and in the age group 5-11 years based on real-world evidence as requested in the outcome of the post Authorization Measure PAM MEA/002.13 (EMEA/H/C/005735/MEA/002.13, dated 08 June 2022). The package leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in section 4.4 of the SmPC.
II/0129	Update of sections 4.2, 4.8 and 5.1 of the SmPC of COMIRNATY 10 µg Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in	15/09/2022	16/09/2022	SmPC and PL	The administration of a third booster dose of Comirnaty in children 5 to 11 years of age is supported by data from clinical study C4591007; this is an-going, randomized, placebo-controlled, Phase 1/2/3 study including healthy children from 6 months to <12 years of age. Efficacy of the booster dose in this age group was inferred by immunogenicity. The immunogenicity was assessed based on: SARS-CoV-2 neutralizing geometric mean titres (GMTs), geometric mean ratio (GMR) and seroresponse. The results from study C4591007 indicated an increase of

	Healthy Children and Young Adults; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				SARS-CoV-2 neutralizing GMT against the wild-type strain, in children 5 through 11 years of age who had no serological or virological evidence of past SARS-CoV-2 infection, from 1253.9, 1-month post-dose 2 (primary series) to 2720.9, 1 month post-dose 3 (booster). This results in a GMR post-dose 3/post-dose 2 of 2.17 (2-sided 95% CI: 1.76, 2.68). The seroresponse rate was almost 100% after the third booster dose, using pre-dose values as reference. This is suggestive of an adequate boosting response. The safety profile after booster dose was consistent with the safety profile known for primary series of Comirnaty administered to children of the same age range. The most frequent adverse reactions were injection site pain, fatigue, headache, myalgia, chills, injection site redness and swelling.
II/0143	B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine	12/09/2022	12/09/2022	SmPC, Labelling and PL	Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. A revised RMP version 7.1 has been approved.
II/0140	B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine	01/09/2022	01/09/2022	SmPC, Labelling and PL	Addition of a new strain (Omicron BA.1) resulting in a new Comirnaty Original/Omicron BA.1 (15 µg tozinameran/ 15 µg riltozinameran)/dose dispersion for injection presentation. The Annex A, the SmPC, the Labelling and the Package Leaflet are updated accordingly. A revised RMP version 6.1 has been approved.

N/0132	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/08/2022	n/a		
IB/0142/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol	01/08/2022	05/08/2022	SmPC	
II/0136	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	21/07/2022	05/08/2022	SmPC and PL	The SmPC section 6.1 has been updated as follows: "Within the 1 month shelf life at 2 °C to 8 °C, up to 48 hours may be used for transportation."
II/0135/G	This was an application for a group of variations. B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation	21/07/2022	n/a		

	B.I.z - Quality change - Active substance - Other variation				
II/0134/G	This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.z - Quality change - Finished product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging	14/07/2022	n/a		

	site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes				
PSUSA/10898 /202112	Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5)	07/07/2022	n/a		PRAC Recommendation - maintenance
II/0131	B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	23/06/2022	n/a		
IAIN/0133/G	This was an application for a group of variations. B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of	15/06/2022	n/a		

	specification limits for medicinal products subject to OCABR				
II/0124/G	This was an application for a group of variations. B.II.f.z - Stability of FP - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	10/06/2022	n/a		
II/0130/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a	02/06/2022	n/a		

	biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.z - Quality change - Finished product - Other variation B.II.b.3.b - Change in the manufacturing process of				

	the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.z - Quality change - Finished product - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol				

	product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0127	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	25/05/2022	n/a		
IA/0128/G	This was an application for a group of variations. B.II.c.4.a - Change in synthesis or recovery of a non-	12/05/2022	n/a		

	pharmacopoeial or novel excipient - Minor change B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change				
II/0125/G	This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.z - Quality change - Active substance - Other variation	12/05/2022	n/a		
N/0113	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/05/2022	n/a		
II/0104	Update of sections 4.2, 4.8 and 5.1 of the SmPC of Comirnaty 30 microgram/dose and section 4.8 of the SmPC of Comirnaty 10 microgram/dose in order to update immunogenicity, safety and efficacy information regarding heterologous booster vaccination based on published literature data; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	22/04/2022	04/05/2022	SmPC and PL	The immunogenicity, safety and efficacy of an heterologous booster dose of Comirnaty 30 µg in individuals 18 years of age and older who have received a primary course comprised of another mRNA vaccine or adenoviral vector vaccine has been assessed. This review took into consideration all available data from clinical studies, post-marketing and real-world evidence. No new safety concerns have been identified. The reviewed literature evidence as well as the recommendations taken for the other mRNA vaccine approved in the EU further supported the shortening of the boosting interval to at least three months after completion of the primary course.

II/0126/G	This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	26/04/2022	n/a		
IB/0123	B.I.z - Quality change - Active substance - Other variation	19/04/2022	n/a		
II/0120/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.1.b - Change in the specification parameters	07/04/2022	n/a		

	and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change				
IB/0122	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	04/04/2022	07/04/2022	SmPC and PL	Update of the product information to extend the shelf life of COMIRNATY 30 µg Concentrate for dispersion for injection (EU/1/20/1528/001) from 9 to 12 months.
II/0116/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -	31/03/2022	07/04/2022	Annex II	

	Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product				
IB/0106/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS	31/03/2022	n/a		
II/0112/G	This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change	24/03/2022	n/a		

	in the manufacturing process B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method				
II/0105	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	24/03/2022	n/a		
II/0121/G	This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol	23/03/2022	07/04/2022	SmPC and PL	
IB/0119/G	This was an application for a group of variations.	22/03/2022	n/a		

	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation				
II/0109/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	10/03/2022	n/a		
II/0087	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing	10/03/2022	n/a		

	authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
II/0115/G	This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch	03/03/2022	n/a		

	release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method				
IB/0114	B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR	03/03/2022	n/a		
IB/0117/G	This was an application for a group of variations.	02/03/2022	n/a		

	B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites				
II/0111	Update of section 4.2 of the SmPC of Comirnaty 30 microgram/dose to lower the age of the booster dose from adults 18 years of age and older to adults and adolescents 12 years of age and older, based on real world evidence collected by the Ministry of Health of Israel. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information (SmPC and package leaflet). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	24/02/2022	28/02/2022	SmPC and PL	SmPC new text A booster dose of Comirnaty may be administered intramuscularly at least 6 months after the second dose in individuals 12 years of age and older. For more information, please refer to the Summary of Product Characteristics.
II/0093	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC of Comirnaty 30 microgram/dose and section 4.8 of the SmPC of Comirnaty 10 microgram/dose in order to update efficacy and safety information after booster dose and change posology recommendations for booster use from "individuals 18 years of age and older" to "individuals 16 years of age and older", based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster	24/02/2022	28/02/2022	SmPC, Labelling and PL	SmPC new text A booster dose of Comirnaty may be administered intramuscularly at least 6 months after the second dose in individuals 16 years of age and older. The relative vaccine efficacy information for participants 16 years of age and older without prior evidence of SARS-CoV-2 infection was 95.3% (95% confidence interval of 89.5% to 98.3%). Relative vaccine efficacy in participants with or without evidence of prior SARS-CoV-2 infection was 94.6%

	efficacy study involving participants ≥ 16 years of age who completed the primary series of BNT162b2 30 µg in Study C4591001, published literature data and post-marketing safety data. The Package Leaflet and Labelling are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				(95% confidence interval of 88.5% to 97.9%), similar to that seen in those participants without evidence of prior infection. The overall safety profile for the booster dose was similar to that seen after 2 doses. For more information, please refer to the Summary of Product Characteristics.
II/0056/G	This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting	17/02/2022	28/02/2022	Annex II	To address specific obligations on quality, the MA Holder provided relevant data and proposed changes to the dossier, in line with the requirements and due dates set by CHMP. With regards to SO1, the MA Holder has provided additional characterisation data as requested. a) The potential for truncated transcripts to produce proteins/peptides was further investigated using a cell-free in vitro expression system. No truncated or other protein species were detected beyond the background bands observed in the negative control sample. The MAH will complement the characterization exercise using the cell-free in vitro translation system with additional tozinameran batches. b) It is sufficiently demonstrated that the major proportion of fragmented species contains the 5'-cap but lacks the poly(A) tail. c) WB results obtained by three different antibodies, specific for the S1 domain, the receptor binding domain and the S2 domain, respectively, were presented and compared to theoretical masses of the S-protein and the

	material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters				subdomains in glycosylated and non-glycosylated forms. It is sufficiently justified that the major band monitored corresponds to the heavily glycosylated S-protein. With regards to SO2, the MA Holder provided additional information to enhance the control strategy, including the active substance and finished product specifications. a) For active substance the acceptance criterion for 5’-Cap has been tightened. For finished product acceptance criteria for osmolality, LNP size, RNA encapsulation, RNA content and lipids content (ALC-0315, ALC-0159, DSPC, cholesterol) and in vitro expression (IVE) assay have been tightened. The revised limits are sufficiently justified and found acceptable. The acceptance criteria for RNA integrity test in active substance and finished product specifications have been previously tightened during VAR IB-31-G. b) A new test method has been introduced and acceptably validated. c) The MAH previously presented data supporting the suitability of the ddPCR method, as being capable of detecting changes in the poly(A) tail content. The accuracy of the ddPCR method is sufficiently addressed. d) The acceptance criteria for RNA integrity test in active substance and finished product specifications have been previously tightened during VAR IB-31-G. The justifications for no further tightening of the finished product specifications for RNA integrity and LNP polydispersity in the current variation have been acceptably justified. e) Additional details have been provided to support the suitability of the IVE assay (cell-based flow cytometry) used for potency determination. f) Evaluation of lipid-related impurities in the finished

	and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.z - Quality change - Active substance - Other variation				product and discussion on ALC-0315 impact on late migrating species (LMS) and RNA integrity were provided and assessed via parallel VAR II-54-G. Based on the provided information, SO1 and SO2 are considered fulfilled. The provided data also fulfils recommendations on analytical methods (REC 10) and additional stability (REC 20). The Annex IIE has been updated as follows: • SO1 (relating to characterisation of the active substance and finished product) is deleted from the list of specific obligations. • SO2 (relating to control strategy, including the active substance and finished product specifications) is deleted from the list of specific obligations.
IB/0110	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	15/02/2022	28/02/2022	SmPC and PL	To update section 4.6 of the SmPC and section 2 of the PL to implement the recommendation on vaccination with Comirnaty in pregnant and breastfeeding women as requested by the CHMP.
II/0108/G	This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.z - Change in test procedure for an excipient - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method	10/02/2022	n/a		

	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation				
IB/0107/G	This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.z - Change in control of excipients in the Finished Product - Other variation	07/02/2022	n/a		
II/0102	Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information 6 months post-dose 2 follow-up for adolescence 12 through 15 years of age based on updated interim results from study C4591001, listed as a specific obligation; this is a Phase 1/2/3, placebo-controlled, observer-blind, interventional, dose-finding, study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-	27/01/2022	04/02/2022	SmPC and PL	Updated efficacy analyses were performed with additional confirmed COVID-19 cases accrued during blinded placebo-controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population. In the updated efficacy analysis of Study 2 in adolescents 12 to 15 years of age without evidence of prior infection, there were no cases in 1,057 participants who received the vaccine and 28 cases out of 1,030 who received placebo. The point estimate for efficacy is 100% (95% confidence

	19 in healthy individuals. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				interval 86.8, 100.0). In participants with or without evidence of prior infection there were 0 cases in the 1,119 who received vaccine and 30 cases in 1,109 participants who received placebo. This also indicates the point estimate for efficacy is 100% (95% confidence interval 87.5, 100.0). For more information, please refer to the Summary of Product Characteristics.
II/0092/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method	03/02/2022	n/a		
II/0090	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	27/01/2022	n/a		
IB/0100	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	24/01/2022	n/a		

II/0080	Update of section 4.4 of the SmPC in order to amend an existing warning on anxiety-related reactions to add hypoaesthesia and paraesthesia and remove tingling sensations following the outcome of the Post-Authorisation Measure MEA-002.8 (EMEA/H/C/005735/MEA/002.8, dated 30 September 2021). Update of section 4.8 of the SmPC in order to add hypoaesthesia and paraesthesia to the list of adverse drug reactions (ADRs) with frequency 'not known' following the outcome of the Post-Authorisation Measure MEA-002.8 (EMEA/H/C/005735/MEA/002.8, dated 30 September 2021). The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	13/01/2022	24/01/2022	SmPC	Following the assessment of clinical trial, literature and post-marketing safety data, a total of 21,793 cases were identified of which approximately 75% occurred within the day after vaccination. When available (~15% of the cases), the duration of the event was reported to be ≤2 days in ~70% of the cases, which is considered a plausible time to onset (TTO). Hypoesthesia and paraesthesia are not sufficiently covered in the product information by the currently included text regarding stress-related reactions. Although approximately 60% of the cases co-reported symptoms associated with an acute stress response/vasovagal episode, the remaining cases were not observed in the context of stress-related reactions (n = 9446). In these cases, co-reported events included reactogenicity adverse drug reactions (ADRs) listed in the product information. Thus, the existing warning on anxiety-related reactions in the SmPC section 4.4 has been amended to remove tingling sensations and add paraesthesia and hypoaesthesia. These ADRs (paraesthesia and hypoaesthesia) have also been added to the list of adverse drug reactions with frequency 'not known' in the SmPC section 4.8.
II/0101	B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol	21/01/2022	04/02/2022	SmPC and PL	The SmPC section 6.3 of the 30 micrograms/dose and 10 micrograms/dose Tris-sucrose formulations (EU/1/20/1528/002-005) has been updated to remove the possibility of distribution at -25°C to -15°C. Distribution is performed under frozen conditions at -90°C to -60°C.
II/0075/G	This was an application for a group of variations. B.II.d.2.c - Change in test procedure for the finished	13/01/2022	n/a		

	product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
PSUSA/10898 /202106	Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5)	13/01/2022	n/a		PRAC Recommendation - maintenance
IA/0103	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	10/01/2022	n/a		
IB/0099/G	This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	10/01/2022	n/a		
IB/0098	B.I.c.1.z - Change in immediate packaging of the AS - Other variation	10/01/2022	n/a		

IB/0096/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure	04/01/2022	n/a		
II/0097	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	21/12/2021	n/a		
II/0089	B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS	16/12/2021	n/a		
II/0054/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient	16/12/2021	24/01/2022	Annex II	To address specific obligations SO4 and SO5, a reassessment of the ALC-0315 and ALC-0159 lipid control strategies was performed including impurity understanding and control, specifications for starting materials, intermediates, and the final ALC-0315 and ALC-0159 lipids and supporting data for method validation and stability data were provided. Evaluation of lipid-related impurities in the drug product and discussion on ALC-0315 impact on late migrating species (LMS) and RNA integrity were

	- Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				provided in the response to SO2 (f). Based on the provided information, SO2 (f), SO4 and SO5 are considered fulfilled. The Annex IIE has been updated as follows: • SO4 relating to excipient ALC-0315 is deleted from the list of specific obligations. • SO5 relating to excipient ALC-0159 is deleted from the list of specific obligations.
IB/0094/G	This was an application for a group of variations.	13/12/2021	n/a		

	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process				
IB/0091	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	09/12/2021	09/12/2021	SmPC and PL	Update of Product Information to extend the shelf life from 6 to 9 months.
IAIN/0095	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	07/12/2021	07/12/2021	SmPC and PL	To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations on 'Signal assessment report on Myocarditis, pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleoside-modified) - COMIRNATY)
II/0086	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	26/11/2021	n/a		
X/0077	Annex I_2.(c) Change or addition of a new strength/potency	25/11/2021	26/11/2021	SmPC, Labelling and PL	

IB/0088/G	This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	23/11/2021	n/a		
IB/0085/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	19/11/2021	n/a		
IB/0084/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.b.3.a - Change in the manufacturing process of	19/11/2021	n/a		

	the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits				
II/0083/G	This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	17/11/2021	n/a		
IAIN/0082	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	16/11/2021	18/11/2021	SmPC and PL	To update section 4.8 of the SmPC and section 4 of the PL to implement the signal recommendation on erythema multiforme.

IB/0081	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	08/11/2021	n/a		
N/0079	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/11/2021	18/11/2021	PL	To update section 2 of the PL regarding the wording on immunity of the third dose.
R/0046	Renewal of the marketing authorisation.	14/10/2021	03/11/2021		Please refer to Scientific Discussion `EMEA/H/C/005735/R/0046`
X/0044/G	This was an application for a group of variations. Extension application to add new pharmaceutical form (dispersion for injection) with a new strength (0.1mg/ml). Update sections 6.4, 6.5 and 6.6 of the SmPC, section 5, 6 and information for healthcare professionals of the PL, section 1 of the Carton Box Label as well as section 1 and 5 of the Vial Label to ensure the correct handling by providing dose verification information about strength, age range, colour information of the flip-off plastic cap and greyscale images. Update sections 4.2 of the SmPC ensure the correct handling in accordance to interchangeability of the medicinal product. Update section 8 of Carton Box Label to clarify expiry date "EXP" by adding storage temperature "(at -90°C to -60°C)" to ensure the correct handling of the medicinal product. Change the name of the active substance from COVID-19 mRNA Vaccine (nucleoside modified) to	14/10/2021	03/11/2021	SmPC, Labelling and PL	Please refer to Scientific Discussion `EMEA/H/C/005735/X/0044`

	Tozinameran. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.3 - Administrative change - Change in name of the AS or of an excipient				
II/0078/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.e.4.b - Change in shape or dimensions of the container or closure (immediate packaging) - The change in shape or dimensions concerns a fundamental part, which may have a significant impact on the delivery, use, safety or stability of the FP	29/10/2021	n/a		
II/0069/G	This was an application for a group of variations. Grouped variation: Type II, B.II.a.3.b.3, Changes in the composition of the finished product to add sodium hydroxide and	28/10/2021	18/11/2021	SmPC, Labelling and PL	The SmPC section 6.1 (EU/1/20/1528/001) has been updated to include the following excipients: Sodium hydroxide (for pH-adjustment) Hydrochloric acid (for pH-adjustment) The Labelling and PL have been updated accordingly.

	hydrochloric acid as pH adjustment excipients (present in the purchased 1500 mM PBS buffer, pH 6.81). Type IB, B.II.b.3.a, Minor changes in the manufacturing process of the finished product to introduce the use of an in-line dilution skid to prepare 50 mM citrate and 150 mM PBS buffers. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product				
IB/0076	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	18/10/2021	n/a		
IB/0074/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	18/10/2021	n/a		
N/0051	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/10/2021	n/a		

II/0072/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.z - Quality change - Finished product - Other variation	11/10/2021	n/a		
II/0073/G	This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	07/10/2021	n/a		

	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier				
II/0071	B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability	06/10/2021	n/a		
IB/0068/G	This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	04/10/2021	n/a		

	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product				
II/0067	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose (third dose) of Comirnaty for individuals 18 years of age and older, based on interim safety and immunogenicity data from the interventional study C4591001, " A Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals". The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	04/10/2021	05/10/2021	SmPC and PL	Please refer to Scientific Discussion `EMEA/H/C/005735/II/0067`
II/0062	Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Comirnaty for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	04/10/2021	05/10/2021	SmPC and PL	Please refer to Scientific Discussion `EMEA/H/C/005735/II/0062`
II/0059	C.I.11.b - Introduction of, or change(s) to, the	30/09/2021	n/a		

	obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
IB/0070	B.I.b.z - Change in control of the AS - Other variation	24/09/2021	n/a		
II/0036	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	16/09/2021	23/09/2021	SmPC and PL	This type II variation updates the product information with updated data (March 2021) from the pivotal study C4591001 with the MAH having conducted an interim analysis containing immunogenicity, efficacy and safety data. The presented efficacy data support the previous conclusions in the initial marketing authorisation approval, and all provided subgroup analyses are in agreement with previous data. A slightly lower point estimate of efficacy (92%) compared to previous analyses was obtained (95%). In addition, the reported interim data in this interim analysis, including reactogenicity and reported adverse events, supports the safety profile of Comirnaty 30µg in subjects ≥16 years of age obtained at the initial authorisation. Based on the safety data provided in this interim analysis, hyperhidrosis, night sweats, decreased appetite, asthenia and lethargy was added with a frequency uncommon to the list of adverse reactions in section 4.8 of the SmPC. For more information, please refer to the Summary of Product Characteristics.

II/0047/G	This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.5.d - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of an in-process test which may have a significant effect on the overall quality of the finished product B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	16/09/2021	n/a		
II/0066	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	13/09/2021	n/a		
IB/0061	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	10/09/2021	23/09/2021	SmPC and PL	- Update section 6.3 of the SmPC to change the shelf life from 6 months to 9 months when stored at the intended storage conditions of -90 to -60 °C - implement Annex IV according to revised CHMP Opinion

					dated 22 July 2021 for procedure EMEA/H/C/005735/II/0030 - amend a mistake in section 4 of the PIL as requested in procedure PAM-MEA-002.6 to indicate that swelling of the face may occur in patients who have had facial dermatological fillers instead of facial cosmetic injections - amend section 4.4 of the SmPC for French and Latvian translations according to the agreed wording with the respective national authorities
II/0065/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	09/09/2021	n/a		
II/0057	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	09/09/2021	n/a		

II/0063/G	This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	02/09/2021	n/a		
II/0052/G	This was an application for a group of variations.	02/09/2021	n/a		

	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method				
II/0040/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	02/09/2021	n/a		
II/0053/G	This was an application for a group of variations.	25/08/2021	n/a		

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation				
II/0060/G	This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	20/08/2021	n/a		

	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product				

	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier				
IB/0058	B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)	17/08/2021	n/a		
IB/0055	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	17/08/2021	n/a		
II/0038/G	This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	22/07/2021	23/07/2021	SmPC and PL	Based on signal detection and evaluation activity in the post-authorisation setting, the section in 4.4 of the SmPC is updated by adding "vaccine stress-related responses" to the already existing warning on anxiety-related reactions (i.e. including examples on stress-related reactions that may occur in association with the vaccination). The provided data support that these anticipated reactions occur related to vaccination. In addition, as agreed by the PRAC, the product information is also updated to add "extensive swelling of the vaccinated limb" and "facial swelling", both at

					frequency unknown, to the list of adverse drug reactions in the section 4.8 of the SmPC. The Package Leaflet is updated accordingly. For more information, please refer to the Summary of Product Characteristics.
II/0049/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	20/07/2021	n/a		
II/0041/G	This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.a - Changes in the manufacturing process of	15/07/2021	n/a		

	the AS - Minor change in the manufacturing process of the AS B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product				
IB/0048/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)	13/07/2021	n/a		
IAIN/0050	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	12/07/2021	13/07/2021	SmPC and PL	To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations from the PRAC Updated Signal assessment report on Myocarditis, Pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleoside-modified) - COMIRNATY) (EPITT no 19712) adopted by PRAC on 08 July 2021
II/0045/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	09/07/2021	n/a		

	B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method				
II/0043	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a	07/07/2021	n/a		

	biological/immunological product				
IB/0042/G	This was an application for a group of variations. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect	18/06/2021	n/a		

	the product information B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product				
II/0039/G	This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation	08/06/2021	n/a		
II/0035/G	This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	01/06/2021	n/a		

	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.z - Quality change - Finished product - Other variation				
II/0030	Extension of the existing indication from "individuals 16 years of age and older" to "individuals 12 years of age and older" for Comirnaty; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	28/05/2021	31/05/2021	SmPC and PL	The application for extension of the indication to include adolescents 12-15 years of age is based on a single pivotal phase 1/2/3 study C4591001. It is an extension of the pivotal efficacy study in adults assessed in the initial approval of Comirnaty. The inferential analysis for the 12-15 year olds which was to demonstrate non-inferior immune responses in this age cohort, compared to subjects 16-25 years from the initial efficacy part of the same study. The effects of Comirnaty in children were investigated in 2,260 children aged 12 to 15 years. The trial showed that the immune response to Comirnaty in this group was comparable to the immune response in the 16 to 25 age group. The efficacy of Comirnaty was calculated in close to 2,000 children from 12 to 15 years of age who had no sign

					of previous infection. These received either the vaccine or a placebo. Of the 1,005 children receiving the vaccine, none developed COVID-19 compared to 16 children out of the 978 who received the placebo. This means that, in this study, the vaccine was 100% effective at preventing COVID-19 (although the true rate could be between 75% and 100%). The most common side effects in children aged 12 to 15 are similar to those in people aged 16 and above. They include pain at the injection site, tiredness, headache, muscle and joint pain, chills and fever. These effects are usually mild or moderate and improve within a few days from the vaccination. The CHMP concluded that the benefits of Comirnaty in this age group outweigh the risks. The CHMP also noted that due to the limited number of children included in the study, the trial could not have detected rare side effects. The committee also noted that EMA's safety committee PRAC is currently assessing very rare cases of myocarditis and pericarditis that occurred after vaccination with Comirnaty, mainly in people under 30 years of age. Currently there is no indication that these cases are due to the vaccine and EMA is closely monitoring this issue. Despite this uncertainty, the CHMP considered that benefits of Comirnaty in children aged 12 to 15 outweigh the risks, in particular in children with conditions that increase the risk of severe COVID-19.
II/0034	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a	28/05/2021	n/a		

	method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol				
IB/0037	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	27/05/2021	n/a		
II/0033/G	This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation	25/05/2021	n/a		
II/0023/G	This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH	20/05/2021	31/05/2021	Annex II	The MAH has submitted additional validation data, which were a condition to the Marketing Authorisation (Specific Obligation SO3; In order to confirm the consistency of the finished product manufacturing process, the MAH should provide additional validation data. Due date: March 2021). Following assessment of the data, Annex IIE (specific obligation to complete post-authorisation measures for a

	where significant assessment is required B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation				conditional marketing authorisation) is updated; SO3 is fulfilled and is deleted from the list of specific obligations.
IB/0031/G	This was an application for a group of variations. Sections 6.3 and 6.6 of the SmPC have been updated to change the storage conditions of the unopened thawed vial from '5 days at 2-8°C' to '1 month at 2-8°C'. An additional text field has been added to the outer packaging to insert the expiry date at 2 to 8°C. B.I.z - Quality change - Active substance - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of	17/05/2021	31/05/2021	SmPC, Labelling and PL	The SmPC, labelling and package leaflet are updated to extend the shelf life of thawed vials from 5 days to 1 monhts at 2-8°C. In addition, section 6.3 of the SmPC is updated in line with CHMP/QWP/159/96 corr. (Note for Guidance of Maximum Shelf-Life for Sterile Products for Human Use After First Opening or Following Reconstitution).

	specification limits for medicinal products subject to OCABR B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product				
IA/0032	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	12/05/2021	n/a		
II/0028/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for	07/05/2021	n/a		

	biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -				

	Replacement/addition of a site where batch control/testing takes place B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0029	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	04/05/2021	n/a		
II/0027	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	27/04/2021	n/a		
II/0022/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study	21/04/2021	n/a		

II/0026	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	20/04/2021	n/a		
IB/0025/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	20/04/2021	n/a		
II/0019	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	15/04/2021	n/a		
II/0016/G	This was an application for a group of variations. Group of two type II variations C.I.3.b consisting of: C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	13/04/2021	14/04/2021	SmPC and PL	This variation pertains to two updates of the section 4.8 of the SmPC to implement the wording agreed by the PRAC following the outcome of the Post Authorisation Measures PAM-MEA-002.1 (EMEA/H/C/005735/MEA/002.1) and PAM-LEG-022 (EMEA/H/C/005735/LEG/022). In this context, 2 new adverse drug reactions (ADRs) (“diarrhoea”, “vomiting”) were added with very common and common frequencies respectively, and the ADR “pain in extremity”

	C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH				was updated with a footnote. In addition, the ADR concerning "hypersensitivity reactions" was further detailed (e.g. "rash, pruritus, urticaria, angioedema") with the relevant frequency categories.
IB/0024/G	This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.z - Stability of FP - Other variation	13/04/2021	n/a		
II/0020/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change	31/03/2021	n/a		

	B.II.c.z - Change in control of excipients in the Finished Product - Other variation				
II/0017/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.1.b - Replacement or addition of a	29/03/2021	n/a		

	manufacturing site for the FP - Primary packaging site B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)				
IB/0021	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	26/03/2021	n/a		
II/0018/G	This was an application for a group of variations. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	26/03/2021	n/a		
IB/0013	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	26/03/2021	14/04/2021	SmPC and PL	
IB/0014	B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	24/03/2021	14/04/2021	Annex II	Update of Annex II of the product information to include an additional active substance manufacturing site.

IB/0015	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	17/03/2021	n/a		
II/0012	B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability	12/03/2021	n/a		
II/0011/G	This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	09/03/2021	n/a		
II/0009	B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the	19/02/2021	23/02/2021	SmPC and PL	The SmPC sections 6.3 and 6.6 have been updated to include information related to the transportation of diluted

	stability studies have not been performed in accordance with an approved stability protocol				and undiluted product at non-frozen storage conditions and to the handling of temperature excursions once removed from the freezer as follows: Unopened vial; Once removed from the freezer, the unopened vaccine can be stored for up to 5 days at 2 °C to 8 °C. Within the 5 days shelf-life at 2 °C to 8 °C, up to 12 hours may be used for transportation. Prior to use, the unopened vaccine can be stored for up to 2 hours at temperatures up to 30 °C. Diluted medicinal product; Chemical and physical in-use stability, including during transportation, has been demonstrated for 6 hours at 2 ºC to 30 ºC after dilution in sodium chloride 9 mg/mL (0.9%) solution for injection. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. Handling of temperature excursions once removed from the freezer Stability data indicate that the unopened vial is stable for up to: • 24 hours when stored at temperatures from -3 °C to 2 °C • a total of 4 hours when stored at temperatures from 8 °C to 30 °C; this includes the 2 hours at up to 30 °C detailed above This information is intended to guide healthcare professionals only in case of temporary temperature excursion. The PL has been updated accordingly.

II/0010/G	This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure	22/02/2021	n/a		
II/0008/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	16/02/2021	n/a		

	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.c.z - Change in control of excipients in the Finished Product - Other variation				

II/0005	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	10/02/2021	n/a		
II/0004	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	04/02/2021	n/a		
IB/0007	To update the dose interval for Comirnaty in sections 4.2, 5.1 of the SmPC and section 3 and section "The following information is intended for healthcare professionals only" of the PL to implement the recommendation of the CHMP. The wording of the dose interval in section 4.2 has been updated with a view to reflect better in section 4.2 the evidence from the submitted data and provide more clear guidance as well as to describe further in section 5.1 the available data underlying this revision. The MAH has also taken the opportunity to introduce a few editorial changes and to provide updated material affected by the change including 'How to prepare and administer poster' and 'Vaccine traceability card' In addition, the company has informed us that they updated the 'Administration video' and the 'Comirnaty website'. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	28/01/2021	02/02/2021	SmPC and PL	
IB/0006	B.II.c.z - Change in control of excipients in the Finished Product - Other variation	28/01/2021	n/a		

II/0003/G	This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation	27/01/2021	n/a		
IB/0001	B.I.d.1.a.4 - Stability of AS - Change in the re-test	26/01/2021	n/a		

	period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
II/0002/G	This was an application for a group of variations. Grouped variation: B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.5.c - Change in pack size of the finished	08/01/2021	08/01/2021	SmPC, Labelling and PL	The change in pack size and change in specifications were approved. The SmPC sections 2, 4.2, 6.5 6.6 has been updated to reflect the following: One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution. In order to extract six doses from a single vial, low dead-volume syringes and/or needles should be used. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microliters. If standard syringes and needles are used, there may not be enough of the vaccine to extract a sixth dose from a vial. If the amount of vaccine remaining in the vial after the fifth dose cannot provide a full dose (0.3 ml), the healthcare professional must discard the vial and its contents. There should be no pooling from multiple vials to make up a full dose, and any unused vaccine should be discarded 6 hours after dilution. The Labelling and PL have been updated accordingly.

	product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products				